Why the study?
The atherogenic process begins in childhood, motivating investigation into the association of cholesterol efflux capacity with vascular markers of subclinical atherosclerosis in healthy young adults.
Is cholesterol efflux capacity associated with vascular markers of subclinical atherosclerosis in healthy young adults?
Is cholesterol efflux capacity associated with vascular markers of subclinical atherosclerosis in healthy young adults?
In healthy young adults, higher cholesterol efflux capacity is associated with a lower risk of subclinical atherosclerosis at 6-year follow-up, highlighting its potential as a protective marker over time.
CEC inversely associates with subclinical markers in healthy young adults; leaves open causal or preventive implications.
The atherogenic process begins already in childhood and progresses to symptomatic condition with age. We investigated the association of cholesterol efflux capacity (CEC) and vascular markers of subclinical atherosclerosis in healthy, young adults. CEC was determined in 2282 participants of the Young Finns study using cAMP treated 3 H-cholesterol-labeled J774 cells. The CEC was correlated to baseline and 6-year follow-up data of cardiovascular risk factors and ultrasound measurements of arterial structure and function. CEC was higher in women, correlated with total cholesterol, HDL-C, and apolipoprotein A-I, but not with LDL-C or apolipoprotein B. Compared to the lowest CEC quartile, the highest CEC quartile was significantly associated with high CRP levels and inversely associated with adiponectin. At baseline, high CEC was associated with decreased flow-mediated dilation (FMD) and carotid artery distensibility, as well as an increased Young's modulus of elasticity, indicating adverse changes in arterial structure, and function. The association reversed with follow-up FMD data, indicating the interaction of preclinical parameters over time. A higher CEC was directly associated with a lower risk of subclinical atherosclerosis at follow-up. In young and healthy subjects, CEC was associated with important lipid risk parameters at baseline, as in older patients and CAD patients, but inversely with early risk markers for subclinical atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Hunjadi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: